A rabbit model of Alzheimer's disease: Valid at neuropathological, cognitive, and therapeutic levels

Journal of Alzheimer's Disease

Volumn 11, Issue 3, 2007, Pages 371-383

  Woodruff Pak, Diana S ^a,b   Agelan, Alexis ^c   Valle, Luis Del ^c  

^a TEMPLE UNIVERSITY   (United States)

^b University School of Medicine   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid ; Cerebellum; Cerebral cortex; Delay paradigm; Eyeblink classical conditioning; Hippocampus; Neuronal loss; Tau; Trace paradigm

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; COPPER SULFATE; DRINKING WATER; GALANTAMINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CEREBELLUM; CHOLESTEROL DIET; COGNITION; CONDITIONING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EYELID REFLEX; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOREACTIVITY; LEARNING; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RABBIT; VALIDITY;

EID: 34447628317     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-11313     Document Type: Article

References (57)

1. G.W. Arendash, D.L. King, M.N. Gordon, D. Morgan, J.M. Hatcher, C.E. Hope and D.M. Diamond, Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes, Brain Res 891 (2001), 42-53.
2. A. Caccamo, S. Oddo, L.M. Billings, K.N. Green, H. Martinez-Coria, A. Fisher and F.M. LaFerla, M1 receptors play a central role in modulating AD-like pathology in transgenic mice, Neuron 9 (2004), 671-682.
3. G. Chen and J.E. Steinmetz, A general-purpose computer system for behavioral conditioning and neural recording experiments, Behav Res Meth Instr & Computers 30 (1998), 384-391.
4. C. Costantini, R.M.K. Kolasani and L. Puglielli, Ceramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified? Alzheimer's & Dementia 1 (2005), 43-50.
5. J.T. Coyle, D.L. Price and M.R. DeLong, Alzheimer's disease: a disorder of cortical cholinergic innervation, Science 219 (1983), 1184-1190.
6. I. Daum, M.M. Schugens, C. Breitenstein, H. Topka and S. Spieker, Classical eyeblink conditioning in Parkinson's disease, Mov Disord 11 (1996), 639-646.
7. D.W. Dickson, A. Wertkin, L.A. Mattiace, E. Fier, Y. Kress, P. Davies and S.-H. Yen, Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease, Acta Neuropathol 79 (1990), 486-493.
8. J.H. Dowson, C.Q. Mountjoy, M.R. Cairns, H. Wilton-Cox and W. Bondareff, Lipopigment changes in Purkinje cells in Alzheimer's disease, J Alzheimers Dis 1 (1998), 71-79.
9. K. Duff, C. Eckman, C. Zehr, X. Yu, C.M. Prada, J. Perez-Tur, M. Hutton, L. Buee, Y. Harigaya, D. Yager, D. Morgan, M.N. Gordon, L. Holcomb, L. Refolo, B. Zenk, J. Hardy and S. Younkin, Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1, Nature 383 (1996), 710-713.
10. M. Ewers, D. Morgan, M. Gordon and D.S. Woodruff-Pak, Associative and motor learning in 12-month-old transgenic APP + PS1 mice, Neurobiol Aging (2006 in press).
11. Y. Fukutani, N.J. Cairns, M.N. Rossor and P.L. Lantos, Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val→IIe) mutation cases: A morphometric investigation, J Neurol Sci 149 (1997), 177-184.
12. O. Ghribi, B. Larsen, M. Schrag and M.M. Herman, High cholesterol content in neurons increases BACE, β-amyloid, phosphorylated tau levels in rabbit hippocampus, Exp Neurol 200 (2006) 460-467.
13. F. Gonzalez-Lima, J.D. Berndt, J.E. Valla, D. Games and E.M. Reiman, Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease, Neuroreport 12 (2001), 2375-2379.
14. M.N. Gordon, D.L. King, D.M. Diamond, P.T. Jantzen, K.V. Boyett, C.E. Hope, J.M. Hatcher, G. DiCarlo, W.P. Gottschall, D. Morgan and G.W. Arendash, Correlation between cognitive deficits and Abeta deposits in transgenic APP + PS1 mice, Neurobiol Aging 22 (2001), 377-385.
15. L. Holcomb, M.N. Gordon, E. McGowan, X. Yu, S. Benkovic, P. Jantzen, K. Wright, I. Saad, R. Mueller, D. Morgan, S. Sanders, C. Zehr, K. O'Campo, J. Hardy, C.M. Prada, C. Eckman, S. Younkin, K. Hsiao and K. Duff, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat Med. 4 (1998), 97-100.
16. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang and G. Cole, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science 274 (1996), 99-102.
17. S.I. Ikeda, D. Allsop and G.G. Glenner, The morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases: Animmunohistochemical study using amyloid beta-protein antibody, Lab Invest 60 (1989), 113-122.
18. S. Jaffar, S.E. Counts, S.Y. Ma, E. Dadko, M.N. Gordon, D. Morgan and E.J. Mufson, Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway, Exp Neurol 170 (2001), 227-243.
19. E.M. Johnstone, M.O. Chaney, F.H. Norris, R. Pascual and S.P. Little, Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis, Brain Res Mol Brain Res 10 (1991), 299-305.
20. Y.-T. Li, D.S. Woodruff-Pak and J.Q. Trojanowski, Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites, Neurobiol Aging 15 (1994), 1-9.
21. C.J. Maynard, A.I. Bush, C.L. Masters, R. Cappai and Q.-X. Li, Metals and amyloid-β in Alzheimer's disease, Int J Exp Path 86 (2005), 147-159.
22. W.R. McAllister, Eyeblink conditioning as a function of the CS-UCS interval, J Exp Psychol 45 (1953), 417-423.
23. A.B. Moore, M.W. Bondi, D.P. Salmon and C. Murphy, Eyeblink classical conditioning to auditory and olfactory stimuli: performance among older adults with and without the apolipoprotein E epsilon 4 allele, Neuropsychol 19 (2005), 437-445.
24. J.W. Moore, N.A. Goodell and P.R. Solomon, Central cholinergic blockade by scopolamine and habituation, classical conditioning, and latent inhibition of the rabbit's nictitating membrane response, Physiol Psychol 4 (1976), 395-399.
25. D. Morgan and B.D. Gitter, Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease, Neurobiol Aging 25 (2004), 605-608.
26. D. Morgan and R.K. Keller, What evidence would prove the amyloid hypothesis? Toward rational drug treatments for Alzheimer's disease, J Alzheimer's Dis 4 (2002), 257-260.
27. J.C. Morris, Is Alzheimers disease inevitable with age? Lessons from clinicopathologic studies of healthy aging and very mild Alzheimer's disease, J Clin Invest 104 (1999), 1171-1173.
28. J.R. Moyer, R.A. Deyo and J.F. Disterhoft, Hippocampectomy disrupts trace eye-blink conditioning in rabbits, Behav Neurosci 104 (1990), 243-252.
29. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari and F.M. LaFerla, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron 39 (2003), 409-421.
30. N. Schneiderman, Interstimulus interval function of the nictitating membrane response of the rabbit under delay versus trace conditioning, J Comp Physiol Psychol 62 (1966), 397-402.
31. B.B. Simon, B. Knuckley and D.A. Powell, Galantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits, Learn Mem 11 (2004), 116-122.
32. P.R. Solomon, E. Levine, T. Bein and W.W. Pendlebury, Disruption of classical conditioning in patients with Alzheimer's disease, Neurobiol Aging 12 (1991), 283-287.
33. P.R. Solomon, S.D. Solomon, E. Vander Schaaf and H.E. Perry, Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure, Science 220 (1983), 329-331.
34. M. Sommer, J. Grafman, K. Clark and M. Hallett, Learning in Parkinson's disease: eyeblink conditioning, declarative learning, and procedural learning, J Neurol Neurosurg Psychiatry 67 (1999), 27-34.
35. D.L. Sparks, Intraneuronal β-amyloid immunoreactivity in the CNS, Neurobiol Aging 17 (1996), 291-299.
36. D.L. Sparks, Cholesterol, copper, and accumulation of thioflavine S-reactive Alzheimer's-like amyloid β in rabbit brain, J Mol Neurosci 24 (2004), 97-104.
37. D.L. Sparks, Y-M. Kou, A. Roher, T.A. Martin and R.J. Lukas, Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations, Ann NY Acad Sci 903 (2000), 335-344.
38. D.L. Sparks, S.W. Scheff, J.C. Hunsaker III, H. Liu, T. Landers and D.R. Gross, Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol, Exp Neurol 126 (1994), 88-94.
39. D.L. Sparks and B. Schreurs, Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease, PNAS 100 (2003), 11065-11069.
40. A. Takashima, T. Honda, K. Yasutake, G. Michel, O. Murayama, M. Murayama, K. Ishiguro and H. Yamaguchi, Acitvation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons, Neurosci Res 31 (1998), 317-323.
41. A.P. Weible, M.M. Oh, G. Lee and J.F. Disterhoft, Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbits, Learn Mem 11 (2004) 108-115.
42. C. Weiss, P.N. Venkatasubramanian, A.S. Aguado, J.M. Power, B.C. Tom, L. Li, K.S. Chen, J.F. Disterhoft and A.M. Wyrwicz, Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice, Neurobiol Dis 11 (2002), 425-433.
43. H.M. Wisniewski, C. Bancher, M. Barcikowska, G.Y. Wen and J. Currie, Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease, Acta Neuropath 78 (1989), 337-347.
44. B. Wolozin, Cholesterol and the biology of Alzheimer's disease, Neuron 41 (2004), 7-10.
45. T.P. Wong, T. Debeir, K. Duff and A.C. Cuello, Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes, J Neurosci 19 (1999), 2706-2716.
46. D.S. Woodruff-Pak, Mecamylamine reversal by nicotine and by a partial alpha 7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning, Behav Brain Res 143 (2003), 159-167.
47. D.S. Woodruff-Pak, R.G. Finkbiner and I. Katz, A model system demonstrating parallels in animal and human aging: Extension to Alzheimer's disease, in: Novel approaches to the treatment of Alzheimer's disease, E.M. Meyer, J.W. Simpkins and J. Yamamoto, eds, Plenum, New York, 1989, pp. 355-371.
48. D.S. Woodruff-Pak, R. Finkbiner and D. Sasse, Eyeblink conditioning discriminates Alzheimer's patients from nondemented aged, NeuroReport 1 (1990), 45-48.
49. D.S. Woodruff-Pak, Y-T. Li, A. Kazmi and W.R. Kem, Nicotinic cholinergic system involvement in eyeblink classical conditioning in rabbits, Behav Neurosci 108 (1994), 486-493.
50. D.S. Woodruff-Pak, Y-T. Li and W.R. Kem, A nicotinic agonist (GTS-21), eyeblink conditioning, and nicotinic receptor binding in rabbit brain, Brain Res 645 (1994), 309-317.
51. D.S. Woodruff-Pak and M. Papka, Alzheimer's disease and eyeblink conditioning: 750 ms trace versus 400 ms delay paradigm, Neurobiol Aging 17 (1996), 397-404.
52. D.S. Woodruff-Pak and M. Papka, Huntington's disease and eyeblink classical conditioning: Normal learning but abnormal timing, J Int Neuropsychol Soc 2 (1996), 323-334.
53. D.S. Woodruff-Pak, M. Papka, S. Romano and Y-T. Li, Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia, Neurobiol Aging 17 (1996), 505-512.
54. D.S. Woodruff-Pak, M. Papka and E.W. Simon, Eyeblink classical conditioning in Down's Syndrome, Fragile X Syndrome, and normal adults over and under age 35, Neuropsychol 8 (1994), 14-24.
55. D.S. Woodruff-Pak and I. Santos, Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease, Behav Brain Res 113 (2000), 11-19.
56. D.S. Woodruff-Pak, R.W. Vogel III and G.L. Wenk, Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning, PNAS 98 (2001), 2089-2094.
57. T. Yamazaki, H. Yamaguchi, Y. Nakazato, K. Ishiguro, T. Kawarabayashi and S. Hirai, Ultrastructural characterization of cerebellar diffuse plaques in Alzheimer's disease, J Neuropathol Exp Neurol 51 (1992), 281-286.